Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close change Change (%) Open High Low

VirBiotechnology news

Latest news

Show more
Tommy Yap 2025 May 22, 16:00

Morning Note: Japan's Core Inflation Spikes; UK Retail Surges; Canada Sales Slow

Morning Note
Frances Wang 2025 May 21, 16:00

What is the TQQQ ETF: What are the risks associated with TQQQ ETF?

ETFs
Tommy Yap 2025 May 21, 16:00

Morning Note: Nvidia Slams China Chip Ban; Bitcoin Climbs on Trade Peace;

Morning Note Tech Cryptocurrencies
Tommy Yap 2025 May 21, 16:00

Morning Note: UK Inflation Surprises Higher; Mideast Tensions Fuel Oil, Gold

Morning Note Commodities
Frances Wang 2025 May 20, 16:00

Palantir Stock Price Analysis: What is the prediction for PLTR?

Stocks
Frances Wang 2025 May 19, 16:00

Stock index news today: ASX 200 goes higher on RBA Rate Cut

Indices
Tommy Yap 2025 May 19, 16:00

Morning Note: RBA Eases Policy; Canada's Inflation Outlook; China Lowers Rates

Morning Note AUD CAD China
Tommy Yap 2025 May 19, 16:00

Morning Note: ECB Easing May Pause; Japan's Economic Slump; US Credit Caution

Morning Note

Info

Spread

0.03

Spread (%)

0.6757 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Market open

Friday

13:31 - 19:59

Tuesday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

637277184

Shares Outstanding

138238000

Earnings Date (Next)

0000-00-00

instr__dividend_date

instr__ex_dividend_date

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

EPS

-4.23

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Markets.com Bonus Trading

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Markets.com Bonus Trading
Trustpilot